Edward L. Pierce
Analyst · Sara Gubins
Thanks, Mike. As Peter mentioned, net income for the quarter was $11.3 million, or $0.21 per share, on record revenues of $401.7 million. Net income was lower than our previously announced estimates due to an $8.4 million increase in amortization of intangible assets and a higher than expected effective tax rate. Excluding the after-tax effects of the increase in amortization and using the effective tax rate for the full year of 43.1% as opposed to the Q4 rate of 45.4%, net income was $16.9 million, or $0.32 per share on a diluted basis. I'll have more to say about these 2 items later. The improvement in our operating and financial results was mainly driven by the inclusion of Apex Systems and 20% year-over-year revenue growth in our other business units. That translates to 16.8% without Nurse Travel. In Q4, Apex accounted for $207.6 million, or 51.7% of total revenues, and grew approximately 14% year-over-year after converting Apex's 2011 results from a 53-week year to a calendar year reporting basis. Excluding Nurse Travel from our results, revenues for the quarter were $380.4 million, up 1.6% sequentially. As announced in our press release, we completed the sale of our Nurse Travel division earlier this week. This division, which was not core to our business, accounted for only 4.1% of pro forma 2012 revenues and 3.4% of pro forma gross profit. This division will be reported as discontinued operations in our Q1 2013 earnings release and first quarter 10-Q. There were approximately 61.3 billing days in the quarter, 1.5 fewer days than the preceding quarter. Our consolidated average bill rate and consolidated bill pay spreads were flat sequentially but down year-over-year due to the inclusion of Apex Systems. Conversion and direct hire revenues for the quarter were $6.8 million, or 1.7% of total revenues, down from $7.4 million, or 1.9% of total revenues, in the preceding quarter. Foreign currency translation affected revenues adversely, $640,000 year-over-year and positively $624,000 sequentially. Gross margin for the quarter was 30.2%, which was within our previously announced range of outcomes and down from 33.2% in Q4 2011. The year-over-year decline was primarily due to the inclusion of Apex Systems, which has a lower gross margin than the legacy businesses on a combined basis. Sequentially, the gross margin dropped 46 basis points, mainly due to the higher growth of our lower margin businesses and lower permanent placement revenues. Excluding Nurse Travel, the gross margin for the quarter was 30.4%, down 48 basis points sequentially. Gross margin for Q4 benefited from $1.1 million in positive adjustments consisting of a $500,000 reduction in our medical malpractice reserve and a $567,000 benefit related to a Belgian payroll tax subsidy that pertained to pre-2012 operations. SG&A expenses for the quarter were $82.7 million, or 20.6% of revenues, up from $79.2 million, or 20.4% of revenues, in the preceding quarter. As you may remember, Q3 benefited from a $1 billion reduction in an earn out obligation. Expenses for the quarter were below the low end of our estimates after adjusting for the acquisition-related expenses, which were not included in our previously announced estimates. The sequential increase in expense was mainly due to 4.2% increase in the average number of consultants and recruiters and others investments to support the company's growth in 2013. Amortization of intangibles was $11.9 million, up $8.5 million from the $3.3 million in Q3. This increase was attributable to the customer relationships intangible asset, which was the primarily identifiable intangible asset acquired in the Apex Systems' purchases. The asset value and related amortization method were finalized in Q4, resulting in an asset value of $92 million in an amortization method that reflected the pattern of which the economic benefits of the asset are used up. The finalization of this asset value and amortization method resulted in an increase of $8.4 million in amortization, $5 million of which related to Q2 and Q3. The effective tax rate for the quarter was 45.4%, up from 42.3% in Q3. The effective tax rate for the full year was 43.1%. Increase in the effective tax rate in Q4 is mainly due to the higher than expected consultant per diems from Apex Systems, which are subject to the 50% meals and entertainment disallowance for federal income tax purposes. Net income for the quarter was $11.3 million, or $0.21 per share, down from $17.4 million, or $0.33 per share, in the preceding quarter. Excluding the $8.4 million increase in amortization of the customer relationship asset and the higher provision for income taxes related to the high effective tax rate expense in Q4, compared with the full year net income was $16.9 million or $0.32 per diluted share. EBITDA for the quarter was $40.4 million. Adjust or adding back equity-based compensation and acquisition-related expenses, adjusted EBITDA was $44.3 million, or 11% of revenues, down from $45.5 million, or 11.7% of revenues, in Q3. Adjusting Q3 for the $1 million benefit from the reduction in the earn out obligation, adjusted EBITDA was flat sequentially. We ended the quarter with cash and cash equivalents of $27.5 million and during the quarter, paid down debt by $12.5 million. Our leverage ratio, which is total debt to trailing 12 months of adjusted EBITDA, was 2.73x at quarter end, down from 3.79x at the close of the Apex acquisition. Adjusting for the sale of Nurse Travel and applying the sales proceeds to pay down debt, the pro forma leverage ratio was 2.7x. Capital expenditures for the quarter were approximately $3.5 million, and $14.4 million for the full year. Accounts receivable were $243 million at quarter end and days sales outstanding for the quarter were 55 days versus 58 days last quarter. With respect to fourth quarter productivity, we averaged 1,622 staffing consultants, and gross profit per staffing consultant was $75,000 compared with $76,000 in the preceding quarter. Finally, a few comments on our financial estimates for 2013. From continuing operations, which excludes Nurse Travel, which, as I mentioned earlier, will be reported as discontinued operations in the future. For Q1 we estimate revenues of $375 million to $380 million, gross margin of 29.4% to 29.7%, net income of $8.8 million to $10.5 million, earnings per share of $0.16 to $0.19 and adjusted EBITDA of $31 million to $34 million. These estimates reflect normal seasonality in the business, in which gross margins are down sequentially due to the reset of payroll taxes. SG&A expenses are higher sequentially due to headcount added in Q4 and Q1 to drive revenue growth for the year. For the full year, we estimate revenues of $1.6 billion to $1.66 billion, gross margin of 30.3% to 30.5%, net income of $56 million to $60 million, earnings per share of $1.02 to $1.10 and adjusted EBITDA of $164 million to $170 million. These estimates do not include any acquisition-related expenses or synergy savings from our integration efforts. Now, I'll turn it back to Peter for some closing remarks before we it open up for questions. Peter?